Exposures to silica dust, solvents or heavy metals increase the likelihood of developing various forms of myositis, ...
US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...
Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...
A study has shed new light on the mechanisms behind idiopathic inflammatory myopathies (myositis), a group of systemic ...
The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...
The positive predictive value (PPV) of myositis antibodies for diagnosing myositis and its related conditions differs by individual antibody type. Greater diagnostic accuracy is associated with ...
GlobalData on MSN1d
Abcuro secures $200m as it eyes approval for rare muscle disease drugThe funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...
Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback